Phase 2 drug metabolic enzymes appear to be affected in a cytokine-specific manner, as infection resulted in a significant downregulation of several genes encoding hepatic uridine 5′-diphospho-glucuronosyltransferases (UGT) (Stanke-Labesque et al., 2020). Here, SLC35A2 is linked to infection.